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Abstract
Purpose Pneumatic compression devices (PCDs) are used
in the home setting as adjunctive treatment for lymphedema
after acute treatment in a clinical setting. PCDs range in
complexity from simple to technologically advanced. The
objective of this prospective, randomized study was to deter-
mine whether an advanced PCD (APCD) provides better out-
comes as measured by arm edema and tissue water reductions
compared to a standard PCD (SPCD) in patients with arm
lymphedema after breast cancer treatment.
Methods Subjects were randomized to an APCD (Flexi-
touch system, HCPCS E0652) or SPCD (Bio Compression
2004, HCPCS E0651) used for home treatment 1 h/day for
12 weeks. Pressure settings were 30 mmHg for the SPCD
and upper extremity treatment program (UE01) with stan-
dard pressure for the APCD. Thirty-six subjects (18 per
group) with unilateral upper extremity lymphedema with at
least 5% arm edema volume at the time of enrollment, com-
pleted treatments over the 12-week period. Arm volumes were
determined from arm girth measurements and suitable model
calculations, and tissue water was determined based on meas-
urements of the arm tissue dielectric constant (TDC).
Results The APCD-treated group experienced an average of
29% reduction in edema compared to a 16% increase in the
SPCD group. Mean changes in TDC values were a 5.8%
reduction for the APCD group and a 1.9% increase for the
SPCD group.
Conclusion This study suggests that for the home mainte-
nance phase of treatment of arm lymphedema secondary to
breast cancer therapy, the adjuvant treatment with an APCD
provides better outcomes than with a SPCD.
Keywords Lymphedema .Pneumatic compressiondevices .
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Introduction
Lymphedema is a condition resulting from lymphatic dys-
function in which persistent swelling exists due to an ab-
normal accumulation of protein-rich fluid in an extremity or
other body region and is accompanied by marked subcuta-
neous and skin changes as the condition worsens [1]. Pri-
mary lymphedema is caused by the abnormal development
of the lymphatic system and may present at birth, during late
adolescence, or in early adulthood. Secondary lymphedema
results from extrinsic damage or obstruction of the lym-
phatics. In developed countries, breast cancer treatment is
recognized as the major cause of secondary lymphedema
[1–3]. The incidence of breast cancer-related lymphedema
rises dramatically from 3 to 15% after sentinel node biopsy,
to 10–20% after complete axillary dissection, and 30 to 50%
with subsequent radiotherapy [4–7]. Recent data obtained
from fluorescent lymphatic imaging suggests that some
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patients developing secondary lymphedema may have had a
genetic predisposition to lymphatic malfunction [8, 9]. Cur-
rently, no cure exists for lymphedema, so treatment aims to
ameliorate the swelling, lessen its severity and symptoms,
and impede progression. Effective long-term treatment strat-
egies are, therefore, crucial.
The traditional initial treatment for lymphedema is com-
plete decongestive therapy (CDT), which consists of manual
lymphatic drainage (MLD), short-stretch compression ban-
daging, decongestive exercises, and skin care [10]. While
this regimen works effectively for most patients when they
are treated in a clinical setting by a well-qualified therapist,
ultimately it is necessary for the patient to attempt to main-
tain the gains and manage this life-long condition in a home
setting. Successful transfer to the home care setting is chal-
lenging. Many patients find the procedures, particularly
those for self-MLD and bandaging, time-consuming and
difficult to carry out, especially if they have physical limi-
tations from comorbidities. Poor patient adherence to pre-
scribed home treatments can result in failure to maintain
progress and may likely negate gains achieved during pre-
vious clinical treatments.
One treatment adjunct that may aid the patient in the
home management setting is use of pneumatic compression
devices (PCDs). PCDs utilize an air compressor unit that
attaches to a garment or series of garments. The garment
chambers sequentially inflate and deflate applying pressure
against the skin thereby creating a treatment effect. PCDs
range from simple single-chamber or multichamber devices
with limited adjustability, to advanced devices with more
garment options and a wide array of treatment options and
adjustability to address different clinical needs such as fi-
brosis, truncal swelling, chronic wounds, or localized swell-
ing. The adjustability and expanded programs available with
many advanced PCDs (APCDs) provide for faster and more
succinct cycles of pressure and relaxation with compression
levels better approximating those applied with MLD [11].
Some APCDs provide specific garments enabling truncal
treatment, which is deemed fundamental in clinical training
in MLD technique and is based on lymphatic architecture
and animal experimental evidence [11–14].
Validation of treatment and outcome advantages associ-
ated with advanced devices in comparison to standard devi-
ces is lacking. Although, several studies have reported
positive results with use of PCD treatment [15–25], it is
difficult to compare outcomes from the initial body of
evidence regarding early PCDs with more current APCD
options. Many of these studies are over 10 years old and
lack sufficient detail about the devices studied to enable
comparisons to aid in device selection or treatment protocol
with regard to currently marketed devices, especially the
newer PCD technologies [26]. Of significance, most of the
treatment protocols studied were not practical or sustainable
for long-term, as treatment durations ranged from 2 to
6 hours daily [26] and/or were limited to lower extremity
lymphedema [19, 24]. One comparative study has been
conducted to date regarding APCDs. A pilot RCT investi-
gated the home maintenance phase of ten patients who had
unilateral breast cancer-associated lymphedema of the arm
by comparing self-MLD with an APCD for 1 h each day for
14 days followed by crossover to the other treatment with a
1-week washout period before each treatment [27]. Post-
treatment arm volume and patients’ mean weight signifi-
cantly decreased after using the APCD but not after self-
administered MLD [27].
Despite development of some clinical consensus that
APCDs may yield better outcomes for some patients than
simple PCDs [28, 29], further published evidence is lacking.
Based on the theoretical advantages potentially offered by
an APCD as supported by prior literature, we hypothesized
that an APCD would result in better outcomes than less
advanced systems when used in the home environment.
The specific goal of this study was to test this hypothesis
by evaluating and comparing changes in arm edema volume
and local tissue water content achieved with the use of either
an APCD or standard PCD (SPCD) system.
Materials and methods
This study was a prospective, randomized controlled trial in
which patients were consented and randomized in a 1:1 ratio
to either a SPCD (Bio Compression 2004 Sequential Circu-
lator PCD, Bio Compression Systems, Moonachie NJ,
USA) or an APCD (Flexitouch system, Tactile Systems
Technology, Inc., Minneapolis MN, USA). Each device
was to be used for the home maintenance phase of treatment
for secondary upper extremity lymphedema caused by
breast cancer treatment.
Three centers participated in this study: Healing Hands of
Lymphatics (Hallandale Beach, FL, USA), Washington
Hospital Healthcare System (Fremont, CA, USA), and Me-
morial Hermann Hospital (Texas Medical Center, Houston,
TX, USA). The trial was approved by the following institu-
tional review boards (IRBs): Sterling IRB (3139, 02-16-
2009), Washington Hospital Healthcare System IRB (02-
19-2009), and University of Texas IRB (HSC-MS-10-
0050, 03-05-2009). This study was conducted in accordance
with US and international good clinical practices (FDATitle
21, part 812 and International Conference on Harmonization
guidelines), applicable government regulations and institu-
tional research policies and procedures. Subjects who were
recruited from the participating lymphedema treatment cen-
ters had either previously sought or were currently seeking
treatment for their lymphedema. A total of 36 patients
(equally divided between standard and APCD use) form
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the basis of the present report. These 36 patients were fully
evaluated for edema volume changes after 12 weeks of in-
home treatment and 28 of these patients (also equally divid-
ed) were evaluated for changes in arm tissue water content.
Eligibility
Subjects had to be at least 18 years old and able to give
informed consent. A confirmed diagnosis of upper extremity
lymphedema secondary to breast cancer treatment was
required, and each patient had to have previously completed
intensive lymphedema treatment (phase I) and discharged to
home maintenance (phase II) but the patient must not have
received in-home PCD therapy for the past 3 months. Fur-
ther, at least 5% edema volume needed to be present at the
time of study enrollment.
Baseline data
Demographic information including age, gender, race, arm
dominance, and BMI was collected at baseline. Medical
history data collected included type of surgery, chemother-
apy, radiation, time since surgery, and number of nodes
removed, if applicable. Table 1 summarizes these data for
all subjects separated by randomly assigned groups (SPCD
vs. APCD).
Tests for baseline group differences in age and BMI,
number of nodes that were removed during the subjects’
initial surgery as well as time between surgery and study
start showed no significant difference as evaluated via inde-
pendent t tests (Table 1). Tests for normality of the data for
the number of nodes that were removed during the subjects’
initial surgery as well as time between surgery and study
start (Shapiro–Wilk test) indicated non-normality (p<
0.001), so this data was tested using the Mann–Whitney
test. Results (Table 1) show insignificant differences in both
parameters between groups. Further, tests for baseline group
differences in race, affected arm side, dominant arm side,
type of surgery, radiation treatment, and chemotherapy also
showed no significant difference as evaluated via Pearson’s
Chi Square analyses (Table 1). Thus, with respect to these
demographic variables, the two groups were well balanced
at entry into the study.
Arm girth measurements
Arm circumferences (girths) were measured with a Gulick II
tape measure. The Gulick II tape measure (model 67020;
Country Technology, Inc., Gay Mills, WI) has a tension
meter attached, so that the tape’s tension can be standardized
during measurement. The no-stretch, retractable tape is cal-
ibrated to indicate precisely a 4-once tension. During
Table 1 Baseline comparison of
the advanced and standard PCD
groups (APCD, SPCD)




bBio Compression 2004 Sequen-
tial Circulator, HCPCS E0651
cp-value based on Mann–Whit-
ney test
Characteristic APCDa (n018) SPCDb (n018) p value
Age 63.9±12.2 59.7±12.6 0.315
BMI 28.2±4.6 30.6±7.4 0.258
Months between surgery and study start 105.9±119.7 75.4±73.4 0.815c
Number of nodes removed 11.9±8.7 12.6±11.2 0.987c
Surgery type 0.441
Mastectomy 12 (67) 15 (83)
Lumpectomy 6 (33) 3 (17)
Radiation therapy 0.717
Yes 12 (67) 13 (72)
No 6 (33) 5 (28)
Chemotherapy 0.675
Yes 15 (83) 14 (78)
No 3 (17) 4 (22)
Race 0.725
Caucasian 10 (56) 13 (72)
African American 3 (17) 3 (17)
Hispanic 2 (11) 1 (6)
Other 3 (16) 1 (6)
Affected arm 0.724
Left 13 (72) 11 (61)
Right 5 (23) 7 (39)
Surgery on dominant side 5 (28) 7 (39) 0.725
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measurement, the end of the tensioning mechanism is pulled
until the calibration point, a silver disk separated by two
colored beads, is seen. Girth measurements were done with
subjects seated and their arms extended in front of them with
their palm resting on their ipsilateral knee. Girths were
measured at 4-cm intervals starting at the ulnar styloid and
ending at the last full 4-cm interval near the axilla. Girth
measurements were taken primarily by one person at each of the
three sites. These individuals were all experienced lymphedema
therapists who routinely perform these measurements daily in
their active lymphedema practice. The girth values served as
inputs to a software algorithm that calculates arm volume based
on a standardized and validated frustum model [30–33]. Abso-
lute arm volumes of affected arms (VA) and contralateral arms
(VC) at week 0 and week 12 were determined from these girth
measurements. Edema volumes in milliliters (EVOL) were cal-
culated as (VA−VC) and percentage edema volume (%EVOL)
was calculated as 100(VA−VC) / VC.
Local tissue water
An index of local skin tissue water was measured using the
tissue dielectric constant (TDC) method [34, 35]. The TDC
is the electrical dielectric constant or permittivity of the
tissue and is expressed relative to the permittivity of a
vacuum, so it is a dimensionless number. Its measured value
depends on the amount of water within the measurement
volume; pure water has a value of about 78. With the probe
and frequency used (300 MHz), the TDC value reflects both
free and bound water within the measurement volume to a
skin depth of about 2.5 mm. TDC values were obtained at
weeks 0 and 12 using a commercial device (MoistureMeter-
D, Delfin Technologies, Ltd., Kuopio, Finland). TDC meas-
urements were made on both anterior forearms at a stan-
dardized site along the forearm midline located 8 cm distal
to the antecubital crease. Triplicate measurements at each
site were obtained by placing the probe in contact with the
skin and held in position using gentle pressure. These trip-
licate measurements were averaged to produce a single
value for each site. These measurements were made in 28
subjects (14 subjects in the APCD group and in 14 subjects
in SPCD group) all coming from a single center, Healing
Hands of Lymphatics (Hallandale Beach, FL), per protocol.
Measurements were made at week 0 prior to the start of
treatment and at week 12 at the end of treatment. This
method for assessment has been extensively used to assess
localized skin water and its change [34–38].
Protocol and procedures
After consent and randomization, subjects were seen in the
clinic for their baseline (week 0) measurements. Each sub-
ject was seen and examined by a study clinician who
provided the subject with specific instructions to ensure
thorough understanding of the operation of the device to
which they were assigned. Subjects were reminded to con-
tinue the other components of their home care including
exercise, skin care, and compression garment use as previ-
ously recommended by their clinician. Subjects were also
instructed to complete the daily usage log pertaining to the
assigned device and to document treatment compliance and
were instructed on the treatment protocol.
Treatment protocol
The assigned PCD was used for home treatment 1 h/day in
addition to existing routine care, which included compres-
sion garment wear for 23 h per day. The SPCD consists of a
gradient, sequential pneumatic compressor weighing 6 lbs
with dimensions of 5.5″×12″×8″. It can be set within a
pressure range of 0–125 mmHg. The compressor unit
attaches to an arm garment with four compression chambers
ranging from approximately 15 to 24 cm wide depending on
garment size. Chambers inflate sequentially at a rate of 18 s/
chamber until all chambers are fully inflated for a total
inflation time of approximately 72 s. Full garment inflation
is then held for 22 s before all chambers simultaneously
deflate for 18 s. Garments have zipper closures and are
made of 200 denier nylon-coated Oxford with 3 mils of
polyurethane. The SPCD was set according to the manufac-
turer’s suggested setting of 30 mmHg.
The APCD consists of an electronic controller that attaches
to three garments that treat the full upper extremity, which
includes the arm, adjacent chest, and truncal quadrant. The
controller unit weighs 8 lbs with dimensions of 10.4″×9.8″×
4.7″. The garment set contains 26–28 (depending on garment
size) narrow, curved chambers ranging from 3.8 to 4.4 cm
wide which wrap around to follow the contours of the limb
and trunk and close with hook and loop fasteners. The outer
fabric of the garment is made of 100% nylon and is latex free.
The inflation/deflation cycle for each chamber is 1–3 s in
duration. No two chambers are fully inflated simultaneously.
The APCD system has 13 therapy program options and
applies light, variable pressure to the trunk and the affected
arm using multichambered, inflatable, and stretchable fabric
garments. The APCD was set to the full upper extremity
program (UE01) at the device’s standard pressure setting
according to the manufacturer’s suggested settings. Published
data indicates that this standard setting applies between 9.0±
4.2 mmHg and 13.7±4.8 mmHg to the forearm during the
standard treatment program [39].
Data analysis
The goal of the main study analysis was to evaluate possible
differential effects of device treatment on edema volume and
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local tissue water. Possible differences between devices
were assessed using a general linear model (GLM) for
repeated measures (SPSS v13) with week (week 12 vs. week
0) as the within-subject repeated measure and device (stan-
dard or advanced) as the between-subjects factor. The sig-
nificance level for the acceptance of a device effect was a
priori set to a p value of 0.05 as determined for device–week
interaction. The edema volume analysis included 18 sub-
jects in the APCD group and 18 in the SPCD group. The
local tissue water analysis included 14 subjects in each
group. Possible differences in parameters between groups
or differences between arms at week 0 and week 12 were
separately tested using t tests for independent samples.
Additional endpoints that were evaluated were the num-
ber/severity of adverse events. Primary safety endpoints
included any signs or symptoms of acute infection or other
adverse clinical event defined as any symptom, sign, illness,
or experience that developed or worsened in severity during
the course of the study. Serious adverse events were defined
as an event that is fatal, life threatening, requires hospitali-
zation, or if left untreated could lead to persistent disability.
Results
Arm volumes, edema volumes, and tissue water results are
given as mean ± standard deviation and summarized in
Table 2. At baseline (week 0), there were no significant
between-group differences in affected or control arm vol-
umes, edema volume, or TDC values of affected or control
arms. Contrastingly, and as expected, affected arms had
significantly greater TDC values than control arms indicat-
ing greater skin tissue water of the affected arm. The GLM
repeated measures analysis showed a significant group by
week interaction for both edema volume and for affected
arm TDC values but no interaction for TDC values of the
control arm. This is consistent with a significant device
treatment effect characterized by a week 0 to week 12
edema volume change of −118±170 ml for the advanced
group and +6.3±216 ml change for the standard group.
Figure 1 is a box plot showing these changes in edema
volume from week 0 to week 12. Negative values denote
reductions in edema volume. These absolute changes corre-
spond to changes in percentage edema volume of −29±44%
for the advanced group vs. +16±63% for the standard (p0
0.018). Repeated measures analysis also showed a signifi-
cant group by week interaction for the affected arm TDC
value with the advanced group demonstrating a reduction in
TDC of −3.1±4.9 as compared to +0.4±3.9 for the standard
group (p00.05). These absolute values correspond to a
mean reduction in TDC value of 5.8% for the advanced
group and a 1.9% increase for standard group.
Device compliance was very good in both groups with
the APCD group completing a total of 1,434 treatments out
of 1,512 (95%) and the SPCD group completing 1,494 out
of 1,512 (99%). Per patient report, compliance with the
other home treatment components between the groups was
very similar, with the biggest difference in exercise. In both
groups, 78% (14 per group) reported compliance with daily
compression garment wear with 22% (four per group)
reporting partial compliance defined as garment wear less
than 3 days/week or only during the night. Likewise, the
same number in each group, 14 (67%), reported performing
self-massage daily or almost daily, with 33% or six in each
group reporting infrequent compliance with daily self-
massage. Compliance with skin care was high and equal in
both groups with 94% (17) in each group reporting daily
compliance. Regarding exercise, 83% (15) of the SPCD
group reported daily exercise compared to 61% (11) in the
APCD group. It is important to note that subjects were
instructed to continue with all other home treatment compo-
nents they were doing prior to starting this study.
Table 2 Volume and TDC result summary
Group Week 0 Week 12 Week by groupb
APCD SPCD p valuea APCD SPCD p valuea
Affected arm volume (ml) 3,102±755 3,104±966 0.994 2,952±724 3,013±773 0.645 0.141
Control arm volume (ml) 2,546±657 2,573±695 0.902 2,514±599 2,537±631 0.912 0.942
Edema volume (ml) 556±318 531±372 0.823 438±344 537±293 0.363 0.050*
Percent edema volume (%) 23.0±13.9 19.9±11.9 0.471 18.2±14.0 21.0±10.7 0.571 0.047*
TDC of affected arm 36.9±9.8 33.2±7.8 0.260 33.8±7.6 33.5±6.6 0.904 0.049*
TDC of control arm 26.2±3.8 25.3±3.6 0.502 25.6±2.4 25.8±3.8 0.907 0.510
Data are mean ± standard deviation. Volume data based on 18 per group, and TDC data based on 14 per group
a As determined by independent t tests between groups
b Significance of week by group interaction
* Statistically significant
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Seven adverse events were recorded that were classified
as “unlikely,” “possibly,” or “definitely” device-related: one
in the APCD group and six in the SPCD group. Five were
further classified as “serious” and one “nonserious”. Table 3
provides the descriptions of these adverse events.
Discussion
The results of this pilot study suggest that application of
the APCD for the home maintenance phase of lymphe-
dema secondary to breast cancer treatment provides better
outcomes as judged by the significant arm edema and
tissue water reductions for the APCD as compared to the
SPCD with fewer complications. Because baseline subject
characteristics were similar between groups and treatment
time and compliance to treatment was essentially the
same, we suggest that the outcome differences may be
associated with differences between device function and
treatment area.
The SPCD utilizes a slower inflation/deflation cycle
wherein the garment takes approximately 72 s to fully
inflate; inflation is held for 22 s and then the air is released
from all chambers simultaneously. This process results in
application of a static pressure to the full arm at a level likely
above that which would compress lymphatic capillaries and
thereby prevent lymph uptake during this interval [40–42].
The APCD utilizes a faster treatment cycle whereby each
chamber inflates/deflates in 1–3 s before the next chamber
inflates. This faster and more succinct cycle of pressure and
release approximates those techniques applied with MLD
[11] and would be consistent with a pressure profile that has
been described to increase lymph drainage [11, 39]. The
resulting dynamic and variable pressures likely induce the
initial lymph capillaries to respond to the pressure changes
occurring in the skin. Furthermore, the more rapidly chang-
ing pressure waves may better facilitate lymph drainage
because this timing better corresponds to the timing of
arterial and respiratory pulses, which are thought to stimu-
late lymphatics [11, 43, 44].
Fig. 1 Changes in edema
volume from week 0 to week 12
(box plot). Circles and star
indicate possible outliers
Table 3 Description of adverse events that might be device-related for advanced and standard PCD groups (APCD, SPCD)
Description Group Device-related Category
Rash on arm SPCD Unlikely Nonserious
Increased arm swelling SPCD Possibly Serious
Breast inflammation; increased swelling and pain; developed infection and fibrosis SPCD Possibly Serious
Increased hand swelling SPCD Definitely Serious
Pain in forearm and numbness in fingers SPCD Definitely Nonserious
Increased swelling of hand and torso; pain in axilla and back SPCD Definitely Serious
Increased swelling of lymph nodes in contralateral axilla APCD Possibly Serious
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In addition, the garments of the APCD studied here
provide specific directional movement that covers more of
the affected region than does the SPCD, therefore treating
more surface area, while following the lymphatic anatomy
of the full upper extremity quadrant. A recently published
pilot study utilizing near-infrared fluorescence imaging
techniques supports the concept that this treatment approach
may enhance lymphatic contractility. Adams et al. reported
that significant increase in lymph vessel contractility was
demonstrated with this same APCD [12].
Although the present findings demonstrated a statistically
significant improvement in both edema volume and tissue
water reductions in favor of the APCD, there remains the
question as to whether the measured differences are of
clinical import. Directly bearing on this question is the result
of a recent study [45], in which it was concluded that even
small limb volume changes have an impact on breast cancer
survivors; as little as 5% volume differential was regarded as
clinically significant with the frequency of signs and symp-
toms significantly increasing as limb volume increased.
These signs and symptoms included tenderness, firmness/
tightness, swelling, heaviness, and aching that ultimately
translated into significant decrements in quality of life
[45]. Although such signs and symptoms were not recorded
in the present study, it is likely that the 29% average reduc-
tion in edema volume noted with subjects using the APCD
would have produced symptom improvement that would like-
ly have translated to quality of life improvements. Along with
the small sample size, the absence of symptom burden, quality
of life and functional outcomes in the present pilot study are
limitations. However, the demonstration of the improved
quantitative outcomes in edema volume and tissue water via
APCD use suggests that further and more in-depth research is
justified. This would include additional research with larger
numbers of subjects and more comprehensive outcome meas-
ures with an ultimate goal of defining subject populations who
would optimally benefit from the use of each type of PCD
device without increased risk of complications.
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